• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Cuprina Holdings (Cayman) Limited

    12/9/25 8:25:53 AM ET
    $CUPR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CUPR alert in real time by email

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 6-K

     

    REPORT OF FOREIGN PRIVATE ISSUER

    PURSUANT TO RULE 13a-16 OR 15d-16

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

     

    For the month of December 2025

     

    Commission File Number: 001-42288

     

    Cuprina Holdings (Cayman) Limited

    (Registrant’s Name)

     

    c/o Blk 1090 Lower Delta Road #06-08

    Singapore 169201

    (Address of principal executive office)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

     

    Form 20-F ☒ Form 40-F ☐

     

     

     

     
     

     

    INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

     

    Other Information

     

    Attached hereto as Exhibit 99.1 are the unaudited condensed consolidated financial statements of Cuprina Holdings (Cayman) Limited (“Cuprina” or the “Company”) as of June 30, 2025 and for the six months ended June 30, 2025 and 2024; and attached hereto as Exhibit 99.2 is the management’s discussion and analysis of financial condition and results of operations for the six months ended June 30, 2025 of the Company.

     

    A copy of the press release entitled “Cuprina Holdings (Cayman) Limited Announces Financial Results for the Six Months Ended June 30, 2025,” issued by the Company on December 9, 2025, is furnished herewith as Exhibit 99.3 and incorporated herein by reference.

     

    Exhibits

     

    Exhibit No   Description
         
    99.1   Cuprina’s Unaudited Condensed Consolidated Financial Statements as of June 30, 2025 and for the six months ended June 30, 2025 and 2024.
    99.2   Cuprina’s Management’s Discussion and Analysis of Financial Condition and Results of Operations for the Six Months Ended June 30, 2025.
    99.3   Press Release – Cuprina Holdings (Cayman) Limited Announces Financial Results for the Six Months Ended June 30, 2025
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

     
     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

      Cuprina Holdings (Cayman) Limited
         
      By: /s/ David Quek Yong Qi
      Name: David Quek Yong Qi
      Title: Chief Executive Officer and Director

     

    Date: December 9, 2025

     

     

     

    Get the next $CUPR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CUPR

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CUPR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cuprina Holdings (Cayman) Limited Announces Financial Results for the Six Months Ended June 30, 2025, and Strategic Initiatives for 2026 Growth

    SINGAPORE, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (NASDAQ:CUPR) ("Cuprina" or "the Company"), a biomedical company developing and marketing products for the chronic wounds, infertility, medical waste recycling, and cosmeceuticals sectors, today  announced its financial results for the six months ended June 30, 2025. "Although our revenue decreased and our net loss increased compared with the same period last year, the first six months of 2025 allowed us to achieve significant advances in both diversifying our product and technology portfolio and expanding our geographic footprint," said Cuprina Chief Executive Officer, Mr. David Quek Yong Qi. Diversification

    12/9/25 8:30:00 AM ET
    $CUPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cuprina Holdings (Cayman) Limited Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency

    SINGAPORE, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (NASDAQ:CUPR) ("Cuprina" or "the Company"), a biomedical company developing and marketing products for the chronic wounds, infertility, and cosmeceuticals sectors, today announced it has received a letter of noncompliance from The Nasdaq Stock Market LLC ("Nasdaq"), dated November 26, 2025, notifying the Company that based on Cuprina's closing bid price for the last 30 consecutive business days, the Company no longer meets the continued listing requirement of Nasdaq, under Nasdaq Listing Rules 5550(a)(2), to maintain a minimum bid price of $1 per share. However, pursuant to Nasdaq Listing Rule 5810(c)(3)(A), th

    11/28/25 8:30:00 AM ET
    $CUPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cuprina Signs MOU with Singapore Biowaste Solutions to Integrate Medical Waste Management Technologies

    SINGAPORE, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (NASDAQ:CUPR) ("Cuprina" or "the Company"), a biomedical company developing and marketing products for the chronic wounds, infertility, and cosmeceuticals sectors, today said it has signed a Memorandum of Understanding (MOU) with Singapore Biowaste Solutions Pte Ltd (SBS), a treater and disposer of bio-medical waste, to explore the integration of Cuprina's medical waste recycling technology into SBS's existing waste management facility in Singapore. The collaboration aims to develop an integrated process that will further reduce reliance on incineration and landfilling, enhance recycling efficiency, unlock new

    10/27/25 8:40:00 AM ET
    $CUPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CUPR
    SEC Filings

    View All

    SEC Form 6-K filed by Cuprina Holdings (Cayman) Limited

    6-K - Cuprina Holdings (Cayman) LTD (0001995704) (Filer)

    12/9/25 8:25:53 AM ET
    $CUPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Cuprina Holdings (Cayman) Limited

    6-K - Cuprina Holdings (Cayman) LTD (0001995704) (Filer)

    11/28/25 8:30:31 AM ET
    $CUPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Cuprina Holdings (Cayman) Limited

    6-K - Cuprina Holdings (Cayman) LTD (0001995704) (Filer)

    11/18/25 8:30:12 AM ET
    $CUPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CUPR
    Leadership Updates

    Live Leadership Updates

    View All

    Cuprina Appoints Dr. Ronald Sherman, Leader in Maggot Debridement Therapy, as Medical and Scientific Director; Secures FDA-approved Medical Maggot License for U.S. Market

    SINGAPORE, July 21, 2025 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (NASDAQ:CUPR) ("CUPR" or "the Company"), a biomedical and biotechnology company dedicated to the development and commercialization of products for the management of chronic wounds and infertility, as well as cosmeceuticals for the health and beauty sector, today announced that Dr. Ronald A. Sherman, a leading innovator in the use of medical maggots to treat chronic wounds, has agreed to join the Company as Medical and Scientific Director in September 2025. Cuprina also announced it has signed an agreement with Dr. Sherman licensing his 2004 FDA clearance to market Lucilia sericata Medical MaggotsTM, the first

    7/21/25 9:00:00 AM ET
    $CUPR
    Biotechnology: Pharmaceutical Preparations
    Health Care